Cimetidine may improve survival in colorectal cancer
the ONA take:
According to new research published in the journal ecancermedicalscience, cimetidine, a histamine-2 receptor antagonist (H2RA), can improve survival in colorectal cancer.
Researchers from the Repurposing Drugs in Oncology (ReDO) project have found that cimetidine has positive effects in colorectal cancer, gastric cancer, melanoma, and renal cell carcincoma. Cimetidine would be an effective repurposed drug for cancer as it is very safe and has preclinical and clinical evidence of effectiveness for numerous types of cancer.
Furthermore, cimetidine is cheap and available over-the-counter. Cimetidine, like famotidine and ranitidine, works by inhibiting histamine receptors in the stomach, thereby decreasing the production of gastric acid.
The ReDO project has also found evidence of anti-cancer properties among clarithromycin, diclofenac, mebendazole, nitroglycerin, and itraconazole. Their findings suggest that these anti-cancer properties should be studied in clinical trials, but pharmaceutical companies lack the financial incentives to do so.
They note that repurposed drugs that are accessible, cheap, and have limited adverse effects are good alternatives to treat cancer in low- and middle-income countries and could reduce costs of treating cancer in developed countries.
Cimetidine, a histamine-2 receptor antagonist (H2RA), can improve survival in colorectal cancer.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|